In contrast, the expression of CDK2, Rb, and p-Rb, the downstream molecules of p21, decreased gradually with the increase in p21 expression, suggesting that ADA promoted the expression of p21 through a p53-dependent pathway, which may represent the mechanism of action of ADA in prostate cancer treatment. The gene discussed is TP53; the disease is Familial prostate cancer.